P
ostsurgical venous thromboembolism remains a common and costly complication associated with significant morbidity and mortality, despite improvements in prophylaxis and perioperative surgical care. Breast cancer survivors who seek immediate or delayed free flap breast reconstruction usually present with multiple risk factors for this potentially preventable complication. In this patient population, such risk factors include for the most part the presence of malignancy, prolonged operative times, and postoperative immobilization. Despite improvements in prophylaxis and perioperative surgical care, however, venous thromboembolism events continue to be common in patients who undergo surgery. Currently, postoperative venous thromboembolism is the third most common safety event in hospitalized patients, causing increased hospital stays, excess mortality, and higher medical costs. 1 flap breast reconstruction remains unclear. A recent survey of plastic surgeons reported a postoperative mortality rate between 1 and 4 percent following major reconstructive procedures. 2 In addition, Kim et al. 3 demonstrated a combined incidence of symptomatic and asymptomatic pulmonary embolism of 3.8 percent in patients who did not receive thromboprophylaxis following autologous breast reconstruction. Of note, when adding thromboprophylaxis in the form of low-molecular-weight heparin, the incidence of pulmonary embolism decreased to 0 percent in this study. Furthermore, in a retrospective review, Liao et al. reported a combined incidence of 0.8 percent for venous thromboembolism events in patients who received thromboprophylaxis following either pedicled or free transverse rectus abdominis musculocutaneous (TRAM) flaps. 4 A subgroup analysis of these data focusing exclusively on women who underwent a free TRAM flap procedure produces a 1.6 percent incidence of deep vein thrombosis in free TRAM flap patients. Other retrospective reviews indicate that clinically detected venous thromboembolism events occur postoperatively in 2 to 6 percent of patients undergoing either pedicled or free flap breast reconstruction. 3, 5 In 2008, the American College of Chest Physicians published their latest generic evidencebased recommendations for venous thromboembolism prophylaxis for surgical patients. 6 These guidelines are evidence-based and currently constitute the most relevant recommendations for venous thromboembolism prophylaxis in plastic surgery. Their generic nature, however, can make them unsuitable for some patients, because of the wide variability in patient-specific venous thromboembolism risk factors. The advantages of "group risk assessment" methods usually pertain to the fact that they focus on the most important risk factor carried by a group of patients-either a surgical procedure or an acute medical illness. Generic venous thromboembolism risk assessment methods, however, may not be appropriate for all individual patients. Moreover, the American College of Chest Physicians guidelines do not compile relevant publications from the plastic surgery literature.
As an answer to this problem, multiple individualized venous thromboembolism risk assessment models have been developed and evaluated clinically. The one published by Caprini 7-9 is widely used in medical and surgical patients for preoperative venous thromboembolism risk assessment. It is a detailed individualized risk assessment model that stratifies patients in four incremental thrombosis risk categories based on the presence of about 40 risk factors, each of which is assigned a relative risk score. [7] [8] [9] Although the Caprini risk scoring model has not been validated prospectively, it has recently been retrospectively validated in over 8000 patients undergoing general, vascular, and urologic surgery. 10 Of note, in 2004, Davison et al. 11 published a set of thromboprophylaxis recommendations that are more relevant to plastic surgery patients. The provided algorithm is based on the American College of Chest Physicians guidelines and also includes a modified version of the Caprini risk assessment model. In addition, the Davison-Caprini model has been shown to retrospectively predict nearly 90 percent of venous thromboembolism events in patients undergoing excisional body-contouring procedures. 12 Assessment of the lower extremity venous system with duplex ultrasound is a noninvasive and easily applicable technique with almost no contraindications. It has become almost universally available and is the most widely accepted imaging modality to the diagnosis of clinically suspected deep vein thrombosis. 13 Although the use of venous duplex ultrasound has thus far not demonstrated sufficient accuracy for routine detection of asymptomatic deep vein thrombosis, venous duplex ultrasound is increasingly used as a screening tool in patients who are unable to communicate their symptoms. 14 The purpose of this study was to objectively assess the incidence of symptomatic and asymptomatic deep vein thrombosis with lower extremity duplex ultrasound in patients who received postoperative thromboprophylaxis after free flap breast reconstruction. Other study outcomes were to assess the safety of low-molecular-weight heparin postoperatively, the incidence of symptomatic pulmonary embolism or sudden death, and the usefulness of the duplex ultrasound as a screening tool in this population.
PATIENTS AND METHODS

Study Design
A prospective cohort study was conducted at Memorial Sloan-Kettering Cancer between December of 2006 and May of 2009. During that period, 225 consecutive women were enrolled in the study. A study group of 118 patients systematically underwent a bilateral lower extremity duplex ultrasound before hospital discharge to assess objectively the status of the lower extremity deep venous system. A retrospective cohort of 107 women who were not systematically screened for deep vein thrombosis was used for comparison.
Consecutive female patients were eligible if they received a free TRAM flap, a free musclesparing TRAM flap, or a deep inferior epigastric perforator (DIEP) flap following either a therapeutic or a prophylactic mastectomy. Patients who underwent other types of autologous breast reconstruction procedures were excluded, as well as women who reported the use of antiplatelet agents or vitamin K antagonists within the week preceding inclusion in the study.
Thromboprophylaxis Regimen
In agreement with the latest American College of Chest Physicians guidelines, 6 all enrolled patients routinely received a triple thromboprophylaxis regimen in the form of postoperative dalteparin, a low-molecular-weight heparin agent; sequential compressive devices before the induction of anesthesia; and early ambulation.
Venous Thromboembolism Assessment and Outcomes Definitions
The study group systematically underwent a bilateral lower extremity duplex ultrasound (Acuson Sequoia 512 Ultrasound System; Siemens Medical Solutions USA, Inc., Mountain View, Calif.) at hospital discharge or at any other point in time based on clinical findings suggestive of deep vein thrombosis. Ultrasounds evaluated the compressibility of the proximal and distal venous systems of the leg from the common femoral vein to the distal calf veins. Patients were not systematically screened for pulmonary embolism or for deep vein thrombosis at sites other than their lower extremities. We defined deep vein thrombosis as an incomplete compression of one or more venous segments. The study group was compared with a retrospective control cohort of women who underwent a duplex ultrasound based only on clinical suspicion. In the presence of clinical suspicion of pulmonary embolism, all enrolled patients underwent a pulmonary embolism protocol computed tomography scan or a ventilation perfusion scan if contrast material could not be used for the imaging study.
All enrolled patients were stratified using the Caprini risk assessment model. After hospital discharge, all patients were reevaluated at approximately 1 month after surgery and asked to report any symptoms or signs of venous thromboembolism or bleeding and rehospitalization at a different institution for such complications.
The primary efficacy outcome was to determine objectively the incidence and clinical importance of asymptomatic or symptomatic deep venous thrombosis in the early postoperative period (defined as 30 postoperative days) in this patient population. Secondary outcomes of interest were the frequency of symptomatic pulmonary embolism and sudden death attributable to venous thromboembolism during the same time period. The primary safety endpoint was the incidence of reoperative hematoma. A bleeding episode was classified as major if it was associated with death, transfusion of at least 2 units of packed red blood cells or whole blood, or a reduction in the hemoglobin level of at least 2 g/dl.
Other safety endpoints of interest were the incidence of total or partial flap loss associated with bleeding complications.
Treatment of Deep Vein Thrombosis
In the event of venous thromboembolism during the study, patients were treated with subcutaneous dalteparin as inpatients or outpatients 15 after a discussion between the hematologist and the patient. Cancer-free patients received anticoagulation for a minimum of 6 months after venous thromboembolism diagnosis. 16 -21 Patients who are not cancer-free were treated indefinitely, as per institutional guidelines.
Data Collection and Statistical Analysis
After approval was obtained from the Institutional Review Board at Memorial Sloan-Kettering Cancer Center, demographic data were collected, including patients' age, admitting diagnosis, breast cancer stage, body mass index, chemotherapy, and radiation therapy. Specific risk factors for deep vein thrombosis were collected, including personal history of coagulation disorders, smoking status, oral contraceptive or hormonal therapy use, length of hospital stay, anesthesia time, and number of days hospitalized. After central data processing, statistical tests were performed using two-sample t tests and Fisher's exact tests, at the 5 percent significance level, to detect differences between the two groups. Formal sample size calculation and power analysis were not performed because this study was not a study of association, and it was not intended to show any difference between two treatments. All analyses were performed using SPSS 17.0 software (Chicago, Ill.).
RESULTS
Patient Characteristics
All patients were considered in the final analysis. The average age was 48.5 years (range, 24 to 69 years) ( Table 1) . A body mass index of 30 kg/m 2 or more was recorded in 22.7 percent of patients. Only 6.2 percent of patients were active smokers. The number of patients with a personal history of venous thromboembolism was very low (Ͻ2 percent), and no patient had a family history of venous thromboembolism. The majority of the 225 enrolled patients had a breast cancer diagnosis (75.1 percent). Overall, 84 percent of patients had a cancer of stage II or less; no patient had stage IV breast cancer. Hormonal therapy use was not significantly different in the intervention group when compared with the control group. All patients were informed to discontinue their hormonal therapy 2 weeks before surgery. There was no other significant difference between the two groups.
Surgical Characteristics
The details of the surgical procedures and complications are presented in Table 2 . The number of patients who underwent a free TRAM flap or a free muscle-sparing TRAM flap (76 percent) was significantly higher in the control group when compared with the study group (53 percent). This is most likely attributable to the chronology of technical advances in abdominal donor flaps utilized for postmastectomy breast reconstruction, with a recent increase in popularity of DIEP flap procedures, due to its possible decrease in abdominal wall morbidity. The same can be said of the number of unilateral procedures: an increasing number of women have recently elected to have bilateral mastectomies and reconstructions for oncologic reasons. This explains the significant decrease in unilateral breast reconstructions in the study group (52 percent) compared with the control group (78 percent). Moreover, the majority of patients (66.7 percent) opted to have breast reconstruction at the time of mastectomy. For immediate breast reconstructions, the length of anesthesia was significantly longer in the study group (10.5 hours) compared with the control group (9.1 hours), as a result of the increased number of bilateral reconstructions in this cohort. Delayed breast reconstructions had similar lengths of anesthesia in both groups. Length of hospital stay was slightly shorter in the study group (5.8 versus 6.4 days), but this difference was not statistically significant. With regard to postoperative complications, the occurrence of reoperative hematoma did not significantly differ in either group (5.9 versus 4.7 percent in the study group and the control group, respectively). In the majority of cases, reoperative hematomas were attributed to flap venous congestion and were not associated with the use of low-molecular-weight heparin. Furthermore, considering that the procedures were all microsurgical breast reconstructions, the threshold for reoperating on suspected hematomas was very low. Flap loss rates did not significantly differ between both groups, with partial flap loss rates of 2.7 percent and total flap loss rates of 1.9 percent. None of the patients enrolled in this study developed heparin-induced thrombocytopenia.
Venous Thromboembolism Events up to 1 Month after Surgery
In the study group, venous duplex ultrasound was systematically performed on average 4.7 days after surgery (typically on the day of or day before discharge). Asymptomatic distal lower extremity deep vein thrombosis was objectively diagnosed in four of 118 patients with duplex ultrasound in the intervention group (3.4 percent), and no deep vein thrombosis was diagnosed in the control group based on clinical suspicion. Characteristics of the four patients diagnosed with deep vein thrombosis are presented in Table 3 . Of the four patients diagnosed with deep vein thrombosis, one of them was characterized as possibly chronic because the venous system contained partially compressible echogenic material. No additional imaging study was performed to clarify the diagnosis in this case because it did not modify the treatment plan. For the total number of patients enrolled in this study, the presence of deep vein thrombosis was clinically suspected in nine patients, none of whom were confirmed with subsequent duplex ultrasound. From discharge to the end of follow-up, no additional episode of symptomatic venous thromboembolism was diagnosed.
Thrombosis Risk Assessment
With respect to the Caprini score, patients were ranked into low-, moderate-, high-, or highest-risk categories. The average Caprini score was 7.6 (Ϯ 0.9) and 7.7 (Ϯ 1.2) in the intervention group and the control group, respectively. This places all enrolled patients at highest risk for venous thromboembolism according to this risk assessment model. 
Number Needed to Screen
The number needed to screen is a way of summarizing the overall benefit of a screening program. It is defined as the reciprocal of the absolute risk reduction and represents the number of people that need to be screened to prevent one adverse event or death. 22 In this study, the number needed to screen was Ϫ29.4 (Table 4) , which means that 29 patients need to be screened to diagnose one deep vein thrombosis event.
DISCUSSION
This is the first epidemiological study to objectively assess the incidence of deep vein thrombosis in women who receive triple thromboprophylaxis following microsurgical breast reconstruction. Our results are encouraging, as they demonstrate that this 7 Although pulmonary symptoms suggestive of pulmonary embolism did occur in some of the patients during the course of this study, investigation with a pulmonary embolism protocol computed tomography scan ruled out this diagnosis in all cases. In our study, there were no sudden deaths attributable to venous thromboembolism in the early postoperative period.
Regarding thromboprophylaxis safety, the frequency of reoperative hematoma after low-molecular-weight heparin prophylaxis was comparable in both groups. Our results are in agreement with previous plastic surgery studies investigating the incidence of bleeding complications with heparin chemoprophylaxis, with demonstrated hematoma rates ranging from 0.6 to 5.3 percent after autologous breast reconstruction procedures. [3] [4] [5] 23 Results presented here are also consistent with the general surgery literature, for which wound hematoma rates of 5.7 percent have been found. 24 Similarly, flap loss rates in our study were low and consistent with previously published results. 5 It is worth noting that the clinical significance of isolated calf deep vein thrombosis [25] [26] [27] remains unclear and its treatment is currently controversial. 28 -32 Reported rates of proximal propagation vary widely between studies, ranging from 4 percent 26 to 28 percent. 25 Moreover, the association between calf vein deep vein thrombosis and pulmonary embolism is also debatable, and the majority of prospective studies that have followed patients with documented calf deep vein thrombosis have reported few cases of clinically overt pulmonary embolism. 29, 32, 33 Furthermore, the rate of development of postthrombotic syndrome after calf deep vein thrombosis is reported to range between 3 and 37 percent. 26, 27 We found that the Caprini risk assessment model lacks discriminatory power in women who underwent autologous microsurgical breast reconstruction, because 96.6 percent of patients without deep vein thrombosis on duplex ultrasound were classified in the highest thrombosis risk group. In addition, as all of the deep vein thromboses diagnosed in our study were clinically silent, physical examination techniques would not likely have been useful in their detection.
In this study, the estimated number needed to screen for deep vein thrombosis was much lower than the values available for dyslipidemia or hypertension screening. 22 The same limitations, however, apply to all estimates of the "number needed." This estimated number needed to screen should be interpreted cautiously because it is derived from the estimated incidence of deep vein thrombosis found in one single study. For results to apply to patient care, the incidence of deep vein thrombosis should be comparable to the one described in the patient population at our institution.
This investigation has certain limitations, namely the small sample of patients diagnosed with deep vein thrombosis, which prevented us from conducting a clinically meaningful subgroup analysis. In addition, the objective incidence of deep vein thrombosis may have been underestimated, as some clinically silent events may have occurred after hospital discharge. Moreover, deep vein thrombosis was diagnosed in this study by screening duplex ultrasonography. Although the value of duplex ultrasonography for diagnosis of symptomatic deep vein thrombosis is widely accepted, limited data are available on the use of this diagnostic tool for screening asymptomatic patients. 34, 35 One recent report comparing ultrasonography with the accepted standard of venography for deep vein thrombosis diagnosis in asymptomatic acutely ill medical patients concluded that ultrasonography underestimated the incidence of proximal and distal deep vein thrombosis. 36 Furthermore, because it was deemed too invasive for the purpose of this study, our positive deep vein thrombosis findings were not confirmed by venography, which is considered the definitive standard in the diagnosis of deep vein thromboses. Thus, there could have been false-positive tests results with duplex ultrasound examination alone. In addition, this study did not detect asymptomatic pulmonary embolism, which would have required systematic patient screening with a pulmonary embolism protocol computed tomography scan or ventilation perfusion scan.
Although this study did not specifically evaluate the use of sequential compressive devices alone, our findings strengthen the recommendations for routine application of triple thromboprophylaxis but also raise questions regarding the necessity of routine ultrasound screening for deep vein thrombosis in this patient population. Further research is required to evaluate whether the detection and treatment of clinically silent deep vein thromboses would result in more good than harm before such screening is routinely implemented.
CONCLUSIONS
This report shows that the objective incidence of asymptomatic deep vein thrombosis is 3.4 percent within 5 postoperative days in women undergoing microsurgical breast reconstruction using abdominally based free flaps. These findings support the use of triple thromboprophylaxis and demonstrate that low-molecular-weight heparin is a safe and effective method for the prevention of venous thromboembolism in this population. From a clinical and public health perspective, however, the knowledge that 3.4 percent of microsurgical breast reconstruction patients develop clinically silent deep vein thromboses has important implications. In an era of financial constraints, one must consider the effectiveness of systematically adding a screening method, such as the duplex ultrasound, to identify asymptomatic deep vein thromboses and begin therapeutic action. Larger-scale clinical trials are necessary to further investigate the usefulness of the duplex ultrasound as a screening tool in this patient population before considering a modification of the standard of care. 
